GLP-1 Drugs -A Trillion-Dollar Employee Care Dilemma: Can Companies Afford Them

GLP-1 Drugs -A Trillion-Dollar Employee Care Dilemma: Can CompanThis program will address the impact on employees, employers, insurance firms, and health care companies.

Please join us and our expert panel to learn more about:

•  Will GLP-1 drugs, originally used and approved for diabetes, now approved for weight loss, and soon to be approved for cardiac indications, upset the economic underpinning/solvency of employer sponsored health plans?
• What are corporate directors really dealing with in cost and care when these drugs are fully available to beneficiaries of all organizations?
• Since corporate benefit charges have largely subsidized governmental programs such as Medicaid and Medicare, what additional impact will cost shifting have on corporate benefit expenditures both directly and indirectly?
• What questions should corporate directors of all organizations be asking their executives about corporate benefit programs and employee wellness tradeoffs?